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Background
The therapeutic success of BRAF inhibitors (BRAFi) is
limited by the emergence of drug resistance [1,2].
Although several mechanisms underlying acquired resis-
tance to BRAFi have been identified [1,2], further studies
are required to disclose their entire spectrum. Altered
expression and/or function of microRNAs (miRNAs) is
involved in tumor onset, progression and drug resistance
[3]. Here, we determined miRNA expression profiles of
melanoma cells sensitive or resistant to the BRAFi dabra-
fenib, and investigated the effect of this drug on their
invasiveness. We also evaluated the consequences of inhi-
biting NF-B or the PI3K/mTOR signalling pathway on
the invasive capacity of dabrafenib-resistant cells.
Materials and methods
The BRAFV600E mutant A375 melanoma cell line, and
its dabrafenib-resistant subline A375R, generated in our
laboratory, were analyzed for the levels of total and
phosphorylated ERK1/2 and AKT, by Western blotting,
and for miRNA expression pattern by using Affymetrix
miRNA 3.1 arrays. A375 and A375R cells were also
exposed to dabrafenib (100 nM, 48 hours) and tested
for: a) in vitro invasion of extracellular matrix (ECM),
under basal conditions and in response to VEGF-A
(Matrigel covered Boyden chambers); b) VEGF-A secre-
tion (ELISA). Finally, in vitro ECM invasion by A375R
cells treated with the NF-B inhibitor NEMO-binding
domain (NBD) peptide (50 μM, 48 hours) or the PI3K/
mTOR inhibitor GSK-2126458 (20 nM, 48 hours), alone
or in combination with 100 nM dabrafenib, was evaluated.
Results
A375R cells showed higher levels of phospho-ERK and
phospho-AKT as compared with A375 cells. Eighty-nine
miRNAs were up-regulated and 47 miRNAs were down-
regulated in the A375R cells with respect to A375 cells.
Gene Ontology analysis of the putative target genes of the
top-ten down-modulated miRNAs revealed “regulation of
cell motion” and “regulation of cell migration” as being
among the most significantly enriched terms. A375 and
A375R cells differently responded to dabrafenib, which
strongly inhibited invasiveness and VEGF-A secretion in
A375 cells, whereas it stimulated these functions in A375R
cells. Treatment of A375R cells with NBD-peptide or with
GSK-2126458 inhibited spontaneous invasion of ECM.
Moreover, both agents completely abrogated dabrafenib-
induced stimulation of ECM invasion.
Conclusions
Our data show that changes in miRNA expression occur
in melanoma cells with acquired resistance to dabrafenib,
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and that invasiveness of these cells is enhanced in the
presence of the drug. They also indicate that targeting
NF-B or the PI3K/mTOR pathway could be an efficient
therapeutic strategy in patients who develop resistance
to BRAFi
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